Cover Image
市場調查報告書

非受體型酪胺酸蛋白質激酶TYK2:開發中產品分析

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 408076
出版日期 內容資訊 英文 68 Pages
訂單完成後即時交付
價格
Back to Top
非受體型酪胺酸蛋白質激酶TYK2:開發中產品分析 Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Review, H2 2017
出版日期: 2017年08月29日 內容資訊: 英文 68 Pages
簡介

本報告提供以非受體型酪胺酸蛋白質激酶TYK2為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您包含最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

非受體型酪胺酸蛋白質激酶TYK2 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Array BioPharma Inc.
  • Bristol-Myers Squibb Company
  • Genentech, Inc.
  • Nimbus Therapeutics, LLC
  • Pfizer Inc.
  • Portola Pharmaceuticals, Inc.
  • Sareum Holdings Plc
  • 武田藥品工業
  • Theravance Biopharma Inc

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1003TDB

Summary:

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by the TYK2 gene. It is involved in intracellular signal transduction by involving in the initiation of type I IFN signaling. It phosphorylates the interferon-alpha/beta receptor alpha chain. It plays an import role in inflammation.

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 9 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Gastrointestinal, Oncology, Central Nervous System, Dermatology, Musculoskeletal Disorders, Ophthalmology and Undisclosed which include indications Ulcerative Colitis, Psoriasis, Autoimmune Disorders, Inflammation, Inflammatory Bowel Disease, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Multiple Sclerosis, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Alopecia, Anaplastic Large Cell Lymphoma (ALCL), Arthritis, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Hypersensitivity, Lupus Erythematosus, Lupus Nephritis, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Systemic Lupus Erythematosus, T-Cell Leukemia, Unspecified, Uveitis and Waldenstrom Macroglobulinemia.

The latest report Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H2 2017, outlays comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)
  • The report reviews Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for
  • Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Overview
    • Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
    • Array BioPharma Inc
    • Bristol-Myers Squibb Company
    • Nimbus Therapeutics LLC
    • Pfizer Inc
    • Portola Pharmaceuticals Inc
    • Sareum Holdings Plc
    • Takeda Pharmaceutical Company Ltd
    • Theravance Biopharma Inc
  • Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drug Profiles
    • ARRY-624 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986165 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cerdulatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NDI-031232 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NDI-031301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NDI-031407 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OST-122 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06700841 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-20347 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SART-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SART-29 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SART-33 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit TYK2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit TYK2 for Psoriasis and Uveitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit TYK2 for Ulcerative Colitis and Autoimmune Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit Tyrosine Kinase 2 for Inflammatory Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TD-1473 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TD-3504 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Dormant Products
  • Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Discontinued Products
  • Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Product Development Milestones
    • Featured News & Press Releases
      • Aug 08, 2017: Theravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis
      • Jun 23, 2017: European Hematology Association: Two is better than one: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study for Relapsed/Refractory NHL
      • Jun 15, 2017: Portola Pharmaceuticals Presents Interim Phase 2a Safety and Efficacy Data for Cerdulatinib at the International Congress of Malignant Lymphoma
      • Jun 14, 2017: Bristol-Myers Squibb To Present on BMS-986165 at the Annual European Congress of Rheumatology (EULAR 2017)
      • May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association
      • May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma
      • Feb 17, 2017: Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization
      • Feb 13, 2017: Theravance Biopharma to Present Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization
      • Nov 29, 2016: Sareum to Present TYK2 Cancer Research Programme at the 2016 AACR-NCI-EORTC International Conference
      • Nov 28, 2016: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition
      • Oct 24, 2016: Sareum Holdings: Successful Outcome from TYK2 Feasibility Study
      • Oct 04, 2016: Theravance Biopharma Announces First Subject Dosed in Phase 1b Clinical Trial of TD-1473 in Patients With Moderate to Severe Ulcerative Colitis
      • Jun 09, 2016: Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor
      • Jun 01, 2016: Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings
      • Apr 14, 2016: Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Array BioPharma Inc, H2 2017
  • Pipeline by Bristol-Myers Squibb Company, H2 2017
  • Pipeline by Nimbus Therapeutics LLC, H2 2017
  • Pipeline by Pfizer Inc, H2 2017
  • Pipeline by Portola Pharmaceuticals Inc, H2 2017
  • Pipeline by Sareum Holdings Plc, H2 2017
  • Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
  • Pipeline by Theravance Biopharma Inc, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top